A New Scoring System Administered by Patients to Identify Moderate-to-Severe Chemotherapy-Induced Peripheral Neuropathy: Final Results of the NEURO-BREAC Trial.

Cancers (Basel) · 2026 · PMC12984089 · PMID 41827769

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

According to the results of the NEURO-BREAC trial, a lower Karnofsky performance score of 70–80, a history of hypertension, and beta blocker treatment were significantly associated with moderate-to-severe CIPN, and a BMI of ≥30.0 kg/m 2 showed a trend.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.